Biodesix – A Lung Cancer Diagnostics Stock

One can’t help but wonder why the Americans are so worried about peanut allergies when 34 million of them use a product every day that slowly kills them. In the United States, cigarette smoking is linked to about 80% to 90% of lung cancer deaths. While we may not be able to pry someone’s cigarettes from their cold dead hands, we may be able to develop tools that help us better treat and diagnose lung cancer.

In our recent piece on A Liquid Biopsy Stock That’s Going Places, we talked about how invasive biopsies will soon be substituted with cancer blood tests, also called liquid biopsies. Being able to detect the presence of cancer using a simple blood draw will transform cancer care as we know it. Today, we’re going to talk about a life sciences company that’s focusing on liquid biopsies and diagnostics for lung cancer.

About Biodesix Stock

Click for company website

Founded in 2005, Denver startup Biodesix has taken in nearly $189 million in funding to apply a multitude of advanced technologies like artificial intelligence (AI

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.